Medication nonadherence in Nigerian heart failure patients: A cross sectional study

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL Journal of Clinical Sciences Pub Date : 2021-07-01 DOI:10.4103/jcls.jcls_1_21
O. Ale, A. Busari, Emmanuel Irokosu, A. Akinyede, S. Usman, Sunday Olayem
{"title":"Medication nonadherence in Nigerian heart failure patients: A cross sectional study","authors":"O. Ale, A. Busari, Emmanuel Irokosu, A. Akinyede, S. Usman, Sunday Olayem","doi":"10.4103/jcls.jcls_1_21","DOIUrl":null,"url":null,"abstract":"Background: Anti-failure therapy is vital to the reduction of morbidity and mortality associated with heart failure (HF). Medication nonadherence (MNA) has been identified as a major limiting factor for the attainment of therapeutic goals. This study aimed to determine the prevalence and characteristics of MNA in HF patients attending Lagos University Teaching Hospital (LUTH), Lagos. Methods: This was a descriptive cross-sectional study involving 202 previously diagnosed HF patients attending an outpatient clinic in LUTH. Data were obtained from patient's medical records and the use of an interviewer-administered questionnaire. Medication Adherence Report Scale 5-items was used to determine MNA. Results: Of the 202 HF subjects, 68% (n = 128) were aged 31–60 years, 65% (n = 132) were females, 58%, (n = 116) were taking ≤4 pills/day, 54.5% were taking pills twice daily, and 72.3% (n = 146) had comorbid conditions. The overall prevalence of MNA was 69.3% with ACE inhibitors having the highest MNA of 73.2% and angiotensin receptor blocker/neprilysin inhibitor having the least MNA of 0%. MNA was independent of age, gender, educational status, pill burden, duration of HF, history of HF admission, functional status, and specific comorbidities (P < 0.05). However, the presence of three comorbidities was associated with lower MNA (P < 0.05). Conclusion: There is a high prevalence of MNA in Nigerian HF patients. Measures aimed at improving adherence are imperative to improve outcomes in these patients.","PeriodicalId":15490,"journal":{"name":"Journal of Clinical Sciences","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jcls.jcls_1_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 2

Abstract

Background: Anti-failure therapy is vital to the reduction of morbidity and mortality associated with heart failure (HF). Medication nonadherence (MNA) has been identified as a major limiting factor for the attainment of therapeutic goals. This study aimed to determine the prevalence and characteristics of MNA in HF patients attending Lagos University Teaching Hospital (LUTH), Lagos. Methods: This was a descriptive cross-sectional study involving 202 previously diagnosed HF patients attending an outpatient clinic in LUTH. Data were obtained from patient's medical records and the use of an interviewer-administered questionnaire. Medication Adherence Report Scale 5-items was used to determine MNA. Results: Of the 202 HF subjects, 68% (n = 128) were aged 31–60 years, 65% (n = 132) were females, 58%, (n = 116) were taking ≤4 pills/day, 54.5% were taking pills twice daily, and 72.3% (n = 146) had comorbid conditions. The overall prevalence of MNA was 69.3% with ACE inhibitors having the highest MNA of 73.2% and angiotensin receptor blocker/neprilysin inhibitor having the least MNA of 0%. MNA was independent of age, gender, educational status, pill burden, duration of HF, history of HF admission, functional status, and specific comorbidities (P < 0.05). However, the presence of three comorbidities was associated with lower MNA (P < 0.05). Conclusion: There is a high prevalence of MNA in Nigerian HF patients. Measures aimed at improving adherence are imperative to improve outcomes in these patients.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
尼日利亚心力衰竭患者的药物依从性:一项横断面研究
背景:抗心力衰竭治疗对降低心力衰竭(HF)相关的发病率和死亡率至关重要。药物依从性(MNA)已被确定为实现治疗目标的主要限制因素。本研究旨在确定在拉各斯拉各斯大学教学医院(LUTH)住院的HF患者中MNA的患病率和特征。方法:这是一项描述性横断面研究,涉及202名在LUTH门诊就诊的先前诊断为HF的患者。数据来自患者的医疗记录和使用访谈者填写的问卷。用药依从性报告量表5项测定MNA。结果:202例HF患者中,68% (n = 128)年龄在31 ~ 60岁之间,65% (n = 132)为女性,58% (n = 116)服药≤4粒/天,54.5% (n = 146)服药2次/天,72.3% (n = 146)有合并症。MNA的总体患病率为69.3%,其中ACE抑制剂的MNA最高,为73.2%,血管紧张素受体阻滞剂/neprilysin抑制剂的MNA最低,为0%。MNA与年龄、性别、教育程度、服药负担、心衰病程、心衰入院史、功能状态、特定合并症无关(P < 0.05)。然而,三种合并症的存在与较低的MNA相关(P < 0.05)。结论:尼日利亚HF患者中MNA患病率较高。旨在改善依从性的措施对于改善这些患者的预后是必不可少的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Clinical Sciences
Journal of Clinical Sciences MEDICINE, GENERAL & INTERNAL-
自引率
0.00%
发文量
15
审稿时长
45 weeks
期刊最新文献
Erratum: Fall risks and health-related quality of life among elderly attending primary healthcare centers in South Western Nigeria: A cross-sectional study Intensive care management of sniper (organophosphate) poisoning secondary to deliberate self-harm: A case report The Journal of Clinical Sciences: From humble beginnings to a dissemination force of scientific research Comparison of Alvarado score, Raja Isteri Pengiran Anak Saleha Appendicitis score, and ultrasonography for diagnosing acute appendicitis: A prospective study Neck circumference and cardiometabolic syndrome in adult patients at a tertiary hospital in Lagos, Nigeria: A cross-sectional study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1